Global Stromal Vascular Fraction Market to Reach $97.6 Million by 2026
SAN FRANCISCO, July 14, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Stromal Vascular Fraction - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.
FACTS AT A GLANCE
Edition: 7; Released: June 2021
Executive Pool: 443
Companies: 25 - Players covered include Cellular Biomedicines Group, Inc.; Cytori Therapeutics, Inc.; GE Healthcare; Genesis Biosystems, Inc.; Human Med AG; InGeneron, Inc.; KYOCERA Corporation; Tissue Genesis Inc. and Others.
Coverage: All major geographies and key segments
Segments: Product Type (Isolation Products, Aspiration Products, Transfer Products); Application (Soft Tissue, Cosmetic, Orthopedic, Other Applications); End-Use (Hospitals, Specialty Clinics, Stem Cell Banks/Laboratories, Other End-Uses)
Geographies: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.
Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry
ABSTRACT-
Global Stromal Vascular Fraction Market to Reach $97.6 Million by 2026
Stromal vascular fraction represents an advanced skin treatment option that is built around stem cell therapy and holds high relevance in the regenerative medicine space. The method involves isolation of cells from adipose tissue of a patient. Obtained through the liposuction process, stromal vascular fraction cells encompass adipose-derived stem cells, endothelial cells, mesenchymal stem cells, leukocytes and tissues containing fat cells. stromal vascular fraction is gaining increasing acceptance across clinical settings for treatment of different chronic conditions. In the recent years, the procedure has witnessed rising significance in diverse areas such as orthopedics, internal medicine, general or plastic surgery and wound healing due to desirable availability, ease of harvest and stable phenotype. Moreover, stromal vascular fraction technique is gaining from several advantages of delivery of these cells through intra-articular injection over surgical implantation, like low cost, less invasiveness and enhanced patient compliance. The global market is slated to receive a significant push from rising number of cosmetic surgeries, increasing incidence of musculoskeletal disorders and growing awareness regarding various merits of stem cell therapy.
Amid the COVID-19 crisis, the global market for Stromal Vascular Fraction estimated at US$75.7 Million in the year 2020, is projected to reach a revised size of US$97.6 Million by 2026, growing at a CAGR of 4.2% over the analysis period. Isolation Products, one of the segments analyzed in the report, is projected to grow at a 4% CAGR to reach US$79.3 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Aspiration Products segment is readjusted to a revised 4.9% CAGR for the next 7-year period. This segment currently accounts for a 16.9% share of the global Stromal Vascular Fraction market. The
SVF isolation products segment dominates market share due to rising demand for these products across clinical settings. The rising demand for aesthetic & reconstructive procedures will further boost market prospects.
The U.S. Market is Estimated at $28.2 Million in 2021, While China is Forecast to Reach $7.7 Million by 2026
The Stromal Vascular Fraction market in the U.S. is estimated at US$28.2 Million in the year 2021. The country currently accounts for a 35.89% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$7.7 Million in the year 2026 trailing a CAGR of 5.5% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.4% and 3.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4% CAGR while Rest of European market (as defined in the study) will reach US$8.1 Million by the end of the analysis period. North America commands a major share of the market, due to increasing demand for reconstructive and aesthetic therapies. The market growth is facilitated by rising awareness pertaining to the use of stem cell therapy to treat several medical conditions and increasing incident of skeletal muscular disorders, including osteoarthritis. The Asia-Pacific region is rapidly emerging as an appealing market on account of continuous expansion of the private healthcare infrastructure and increasing count of private hospitals across rural areas. Stromal vascular fraction is likely to gain from ongoing R&D projects coupled with increasing development and demand for innovative technologies.
Transfer Products Segment to Reach $3.7 Million by 2026
Transfer devices are expected to present new solutions and extend the application scope of stromal vascular fraction. Increasing establishment of private hospitals across urban and rural areas is likely to further bolster the market demand in the coming years. In the global Transfer Products segment, USA, Canada, Japan, China and Europe will drive the 4.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$2.3 Million in the year 2020 will reach a projected size of US$3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$384.2 Thousand by the year 2026. More
MarketGlass™ Platform
Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide.
Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android
About Global Industry Analysts, Inc. & StrategyR™
Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years.
CONTACTS:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
www.StrategyR.com
Email: [email protected]
LINKS
Join Our Expert Panel
https://www.strategyr.com/Panelist.asp
Connect With Us on LinkedIn
https://www.linkedin.com/company/global-industry-analysts-inc./
Follow Us on Twitter
https://twitter.com/marketbytes
Journalists & Media
[email protected]
SOURCE Global Industry Analysts, Inc.
Share this article